Cargando…

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress

Malignant mesothelioma (MM) is a rare and aggressive neoplasm, usually associated with a poor prognosis (5 years survival rate <10%). For unresectable disease, platinum and pemetrexed chemotherapy has been the only standard of care in first line for more than two decades, while no standard treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrino, Matteo, De Vincenzo, Fabio, Cordua, Nadia, Borea, Federica, Aliprandi, Marta, Santoro, Armando, Zucali, Paolo Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911663/
https://www.ncbi.nlm.nih.gov/pubmed/36776840
http://dx.doi.org/10.3389/fimmu.2023.1121557
_version_ 1784885036159336448
author Perrino, Matteo
De Vincenzo, Fabio
Cordua, Nadia
Borea, Federica
Aliprandi, Marta
Santoro, Armando
Zucali, Paolo Andrea
author_facet Perrino, Matteo
De Vincenzo, Fabio
Cordua, Nadia
Borea, Federica
Aliprandi, Marta
Santoro, Armando
Zucali, Paolo Andrea
author_sort Perrino, Matteo
collection PubMed
description Malignant mesothelioma (MM) is a rare and aggressive neoplasm, usually associated with a poor prognosis (5 years survival rate <10%). For unresectable disease, platinum and pemetrexed chemotherapy has been the only standard of care in first line for more than two decades, while no standard treatments have been approved in subsequent lines. Recently, immunotherapy has revolutionized the therapeutic landscape of MM. In fact, the combination of ipilimumab plus nivolumab has been approved in first line setting. Moreover, immune checkpoint inhibitors (ICIs) showed promising results also in second-third line setting after platinum-based chemotherapy. Unfortunately, approximately 20% of patients are primary refractory to ICIs and there is an urgent need for reliable biomarkers to improve patient’s selection. Several biological and molecular features have been studied for this goal. In particular, histological subtype (recognized as prognostic factor for MM and predictive factor for chemotherapy response), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden (widely hypothesized as predictive biomarkers for ICIs in several solid tumors) have been evaluated, but with unconclusive results. On the other hand, the deep analysis of tumor infiltrating microenvironment and the improvement in genomic profiling techniques has led to a better knowledge of several mechanisms underlying the MM biology and a greater or poorer immune activation. Consequentially, several potential biomarkers predictive of response to immunotherapy in patients with MM have been identified, also if all these elements need to be further investigated and prospectively validated. In this paper, the main evidences about clinical efficacy of ICIs in MM and the literature data about the most promising predictive biomarkers to immunotherapy are reviewed.
format Online
Article
Text
id pubmed-9911663
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99116632023-02-11 Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress Perrino, Matteo De Vincenzo, Fabio Cordua, Nadia Borea, Federica Aliprandi, Marta Santoro, Armando Zucali, Paolo Andrea Front Immunol Immunology Malignant mesothelioma (MM) is a rare and aggressive neoplasm, usually associated with a poor prognosis (5 years survival rate <10%). For unresectable disease, platinum and pemetrexed chemotherapy has been the only standard of care in first line for more than two decades, while no standard treatments have been approved in subsequent lines. Recently, immunotherapy has revolutionized the therapeutic landscape of MM. In fact, the combination of ipilimumab plus nivolumab has been approved in first line setting. Moreover, immune checkpoint inhibitors (ICIs) showed promising results also in second-third line setting after platinum-based chemotherapy. Unfortunately, approximately 20% of patients are primary refractory to ICIs and there is an urgent need for reliable biomarkers to improve patient’s selection. Several biological and molecular features have been studied for this goal. In particular, histological subtype (recognized as prognostic factor for MM and predictive factor for chemotherapy response), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden (widely hypothesized as predictive biomarkers for ICIs in several solid tumors) have been evaluated, but with unconclusive results. On the other hand, the deep analysis of tumor infiltrating microenvironment and the improvement in genomic profiling techniques has led to a better knowledge of several mechanisms underlying the MM biology and a greater or poorer immune activation. Consequentially, several potential biomarkers predictive of response to immunotherapy in patients with MM have been identified, also if all these elements need to be further investigated and prospectively validated. In this paper, the main evidences about clinical efficacy of ICIs in MM and the literature data about the most promising predictive biomarkers to immunotherapy are reviewed. Frontiers Media S.A. 2023-01-27 /pmc/articles/PMC9911663/ /pubmed/36776840 http://dx.doi.org/10.3389/fimmu.2023.1121557 Text en Copyright © 2023 Perrino, De Vincenzo, Cordua, Borea, Aliprandi, Santoro and Zucali https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Perrino, Matteo
De Vincenzo, Fabio
Cordua, Nadia
Borea, Federica
Aliprandi, Marta
Santoro, Armando
Zucali, Paolo Andrea
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
title Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
title_full Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
title_fullStr Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
title_full_unstemmed Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
title_short Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
title_sort immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911663/
https://www.ncbi.nlm.nih.gov/pubmed/36776840
http://dx.doi.org/10.3389/fimmu.2023.1121557
work_keys_str_mv AT perrinomatteo immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress
AT devincenzofabio immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress
AT corduanadia immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress
AT boreafederica immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress
AT aliprandimarta immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress
AT santoroarmando immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress
AT zucalipaoloandrea immunotherapywithimmunecheckpointinhibitorsandpredictivebiomarkersinmalignantmesotheliomaworkstillinprogress